Joseph G. Pressey · Pediatric Anaplastic Embryonal Rhabdomyosarcoma: Targeted Therapy Guided by Genetic Analysis and a Patient-Derived Xenograft Study
Follow
Article1 min read·Published Jan 2018Older

Pediatric Anaplastic Embryonal Rhabdomyosarcoma: Targeted Therapy Guided by Genetic Analysis and a Patient-Derived Xenograft Study

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Jan 2018 · 1 min read

In brief

In brief

Case report of an 8-year-old with relapsed anaplastic embryonal rhabdomyosarcoma treated with vorinostat based on genomic profiling revealing BCOR, ARID1A, and SETD2 mutations. The HDAC inhibitor produced transient clinical response, with antitumor activity confirmed in a patient-derived xenograft model showing tumor necrosis.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Therapy for rhabdomyosarcoma (RMS) has generally been limited to combinations of conventional cytotoxic agents similar to regimens originally developed in the late 1960s. Recently, identification of molecular alterations through next-generation sequencing of individual tumor specimens has facilitated the use of more targeted therapeutic approaches for various malignancies. Such targeted therapies have revolutionized treatment for some cancer types. However, malignancies common in children, thus far, have been less amenable to such targeted therapies. This report describes the clinical course of an 8-year-old female with embryonal RMS having anaplastic features. This patient experienced multiple relapses after receiving various established and experimental therapies. Genomic testing of this RMS subtype revealed mutations in BCOR, ARID1A, and SETD2 genes, each of which contributes to epigenetic regulation and interacts with or modifies the activity of histone deacetylases (HDAC). Based on these findings, the patient was treated with the HDAC inhibitor vorinostat as a single agent. The tumor responded transiently followed by subsequent disease progression. We also examined the efficacy of vorinostat in a patient-derived xenograft (PDX) model developed using tumor tissue obtained from the patient's most recent tumor resection. The antitumor activity of vorinostat observed with the PDX model reflected clinical observations in that obvious areas of tumor necrosis were evident follo

Statements in this article

  1. Therapy for rhabdomyosarcoma has generally been limited to combinations of conventional cytotoxic agents similar to regimens originally developed in the late 1960s.

    Established
  2. Identification of molecular alterations through next-generation sequencing of individual tumor specimens has facilitated the use of more targeted therapeutic approaches for various malignancies.

    Established
  3. Malignancies common in children have been less amenable to targeted therapies.

    Established
  4. Genomic testing of embryonal rhabdomyosarcoma with anaplastic features revealed mutations in BCOR, ARID1A, and SETD2 genes, each of which contributes to epigenetic regulation and interacts with or modifies the activity of histone deacetylases.

    Research
  5. The patient was treated with the HDAC inhibitor vorinostat as a single agent based on genomic findings showing mutations affecting histone deacetylase activity.

    Research
  6. The tumor responded transiently to vorinostat followed by subsequent disease progression.

    Research
  7. The antitumor activity of vorinostat observed with the patient-derived xenograft model reflected clinical observations in that obvious areas of tumor necrosis were evident.

    Research

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.